Nasdaq Phvs News Today

Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin...

JMP Securities reissued their market outperform rating on shares of Pharvaris (NASDAQ:PHVS – Free Report) in a research note released on Wednesday, Benzinga reports. JMP Securities currently has a $49.00 price target on the stock. Several other equities analysts also recently issued reports on the stock. Wedbush decreased their price objective on shares of Pharvaris […]

Pharvaris (NASDAQ:PHVS – Free Report) had its price target hoisted by JMP Securities from $40.00 to $49.00 in a research report released on Tuesday, Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Other analysts also recently issued research reports about the stock. Wedbush decreased their price target on shares of […]

Pharvaris (NASDAQ:PHVS – Get Free Report) had its price objective increased by equities research analysts at JMP Securities from $40.00 to $49.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ price target indicates a potential upside of 68.97% from […]

ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor...

Shares of Pharvaris (NASDAQ:PHVS – Get Free Report) gapped down prior to trading on Thursday . The stock had previously closed at $26.10, but opened at $25.51. Pharvaris shares last traded at $25.95, with a volume of 1,906 shares trading hands. Analysts Set New Price Targets Several brokerages have recently weighed in on PHVS. Bank […]

Pharvaris (NASDAQ:PHVS – Free Report) had its price target decreased by Morgan Stanley from $34.00 to $32.00 in a report published on Tuesday, Benzinga reports. Morgan Stanley currently has an overweight rating on the stock. Separately, Wedbush reduced their price objective on shares of Pharvaris from $27.00 to $24.00 and set an outperform rating for […]

Pharvaris (NASDAQ:PHVS – Get Free Report) was the target of a significant decline in short interest in the month of October. As of October 15th, there was short interest totalling 12,500 shares, a decline of 20.9% from the September 30th total of 15,800 shares. Based on an average daily volume of 47,500 shares, the short-interest […]

Pharvaris (NASDAQ:PHVS – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 12,500 shares, a decline of 20.9% from the September 30th total of 15,800 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily […]